February 1, 1994Hormone and Metabolic Research
Characterization of an Inhibitor of Nitric Oxide Synthase in Human-Hand Veins
Key result
l-NMMA significantly decreased bradykinin's maximal venodilatory response from 90% to 39% (p < 0.05), demonstrating its efficacy as a reversible nitric oxide synthase inhibitor in human veins.
Why the study?
Does l-NMMA inhibit bradykinin-mediated, endothelium-dependent dilation in human hand veins?
Population
Human hand veins (using the human hand-vein compliance technique)
Comparison
NG-monomethyl-l-arginine infusion vs Bradykinin alone, and methylene blue
Design
Other
Follow-up
Up to 155 minutes after stopping infusion
Authors
Discussion
Loading...
Member takes
Implication
Supports venous NO research tools; leaves open clinical translation pending higher-level evidence.
Structured PICO
Does l-NMMA inhibit bradykinin-mediated, endothelium-dependent dilation in human hand veins?
P
Population
Human hand veins (using the human hand-vein compliance technique)
I
Intervention
NG-monomethyl-l-arginine (l-NMMA) infusion (e.g., 25 micrograms/min)
C
Comparator
Bradykinin alone, and methylene blue
O
Outcome
Inhibition of bradykinin-mediated, endothelium-dependent venodilationsurrogate
Main Result
Absolute Event Rate: 39% vs 90%
p-value: p=< 0.05
l-NMMA is a highly efficacious and functionally reversible inhibitor of nitric oxide synthase in human veins.
Cite This Study
Bedarida et al. (1994) studied this question. l-NMMA vs. Bradykinin alone (baseline) was evaluated on Bradykinin's maximal venodilatory response (p=< 0.05). l-NMMA significantly decreased bradykinin's maximal venodilatory response from 90% to 39% (p < 0.05), demonstrating its efficacy as a reversible nitric oxide synthase inhibitor in human veins.